Cargando…

Meropenem: continuous or extended infusion?

Detalles Bibliográficos
Autores principales:	Frippiat, Frédéric, Vercheval, Christelle, Layios, Nathalie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7201795/ https://www.ncbi.nlm.nih.gov/pubmed/32370800 http://dx.doi.org/10.1186/s13054-020-02883-w

Ejemplares similares

402 Pharmacokinetics of Extended vs Intermittent Intravenous Infusion of Meropenem in Critically Ill Patients Receiving Continuous Veno-Venous Haemofiltration
por: Frippiat, Frédéric, et al.
Publicado: (2014)

Continuous infusion of meropenem in critically ill patients: practical considerations
por: Taccone, Fabio Silvio
Publicado: (2012)

Pharmacokinetics and Pharmacodynamics of Meropenem by Extended or Continuous Infusion in Low Body Weight Critically Ill Patients
por: Luque, Sonia, et al.
Publicado: (2021)

Clinical outcomes of prolonged infusion (extended infusion or continuous infusion) versus intermittent bolus of meropenem in severe infection: A meta-analysis
por: Yu, Zhenwei, et al.
Publicado: (2018)

Meropenem administration by intermittent infusion versus continuous infusion for the treatment of nosocomial pneumonia
por: Lorente, L, et al.
Publicado: (2005)

Extended Infusion of Meropenem in Neonatal Sepsis: A Historical Cohort Study
por: Cao, Guangna, et al.
Publicado: (2022)

Continuous Infusions of Meropenem in Ambulatory Care: Clinical Efficacy, Safety and Stability
por: Manning, Laurens, et al.
Publicado: (2014)

Therapeutic drug monitoring of meropenem and piperacilin administered in continuous infusion. preliminary data
por: Miralbés Torner, M, et al.
Publicado: (2015)

Impact of cumulative fluid balance on the pharmacokinetics of extended infusion meropenem in critically ill patients with sepsis
por: Pařízková, Renata Černá, et al.
Publicado: (2021)

An investigation of the stability of meropenem in elastomeric infusion devices
por: Foy, Finbarr, et al.
Publicado: (2019)

Continuous infusion versus intermittent administration of meropenem in critically ill patients: a pilot study
por: Thalhammer, F, et al.
Publicado: (1999)

Cerebrospinal Fluid Concentrations of Meropenem and Vancomycin in Ventriculitis Patients Obtained by TDM-Guided Continuous Infusion
por: Tiede, Christoph, et al.
Publicado: (2021)

Effect of extended infusion of meropenem and nebulized amikacin on Gram-negative multidrug-resistant ventilator-associated pneumonia
por: Ammar, Mona Ahmed, et al.
Publicado: (2018)

Extended Versus Intermittent Meropenem Infusion in the Treatment of Nosocomial Pneumonia: A Retrospective Single-Center Study
por: Hyun, Dong-gon, et al.
Publicado: (2023)

Training a Drug to Do New Tricks: Insights on Stability of Meropenem Administered as a Continuous Infusion
por: Venugopalan, Veena, et al.
Publicado: (2018)

Optimal loading dose of meropenem before continuous infusion in critically ill patients: a simulation study
por: Liebchen, Uwe, et al.
Publicado: (2021)

Evolution of Drug Interactions With Antiretroviral Medication in People With HIV
por: El Moussaoui, Majdouline, et al.
Publicado: (2020)

Comparison of the Effectiveness of Prolonged Infusion and Intermittent Infusion of Meropenem in Patients With Sepsis: A Meta-Analysis
por: Lokhandwala, Adnan, et al.
Publicado: (2023)

Intrapulmonary concentrations of meropenem administered by continuous infusion in critically ill patients with nosocomial pneumonia: a randomized pharmacokinetic trial
por: Benítez-Cano, Adela, et al.
Publicado: (2020)

Model-Informed Translation of In Vitro Effects of Short-, Prolonged- and Continuous-Infusion Meropenem against Pseudomonas aeruginosa to Clinical Settings
por: Minichmayr, Iris K., et al.
Publicado: (2022)

Case report: Successful experience using continuous infusion of meropenem in a geriatric patient with hip fracture complicated by sepsis
por: Kadralinova, Assiya, et al.
Publicado: (2023)

Mortierella wolfii–Associated Invasive Disease
por: Layios, Nathalie, et al.
Publicado: (2014)

1547. Modeling Pharmacokinetics and Pharmacodynamics of Meropenem Utilizing a Novel Infusion Method of Bolus to Prolonged Infusion
por: Moore, Sarah E, et al.
Publicado: (2019)

2244. Clinical Outcomes with Extended Infusion (EI) vs. Intermittent Infusion (II) of Cefepime (FEP), Piperacillin/Tazobactam (TZP), and Meropenem (MEM) in Patients with Gram-Negative (GN) Bacteremia
por: Tran, Kieu-Nhi, et al.
Publicado: (2019)

Meropenem-induced hypokalemia and metabolic alkalosis
por: Zaki, Syed Ahmed, et al.
Publicado: (2012)

500 mg as bolus followed by an extended infusion of 1500 mg of meropenem every 8 h failed to achieve in one-third of the patients an optimal PK/PD against non-resistant strains of these organisms: is CRRT responsible for this situation?
por: Honore, Patrick M., et al.
Publicado: (2020)

Response to: 500 mg as bolus followed by an extended infusion of 1500 mg of meropenem every 8 h failed to achieve in one-third of the patients an optimal PK/PD against nonresistant strains of these organisms: is CRRT responsible for this situation?
por: Kothekar, Amol, et al.
Publicado: (2020)

Extended Continuous Infusion of Methylene Blue for Refractory Septic Shock
por: Jaiswal, Abhishek, et al.
Publicado: (2020)

Prolonged continuous infusion of low-dose rIL-2.
por: Janssen, R. A., et al.
Publicado: (1994)

Beta-lactam antibiotics in continuous infusion in critically ill patients
por: Jeurissen, Axel, et al.
Publicado: (2010)

Comparison between meropenem and ceftolozane/tazobactam: possible influence of CRRT
por: Honore, Patrick M., et al.
Publicado: (2022)

Investigation of meropenem stability after reconstitution: the influence of buffering and challenges to meet the NHS Yellow Cover Document compliance for continuous infusions in an outpatient setting
por: Jamieson, Conor, et al.
Publicado: (2020)

Pharmacokinetic/Pharmacodynamic Target Attainment of Continuous Infusion Piperacillin–Tazobactam or Meropenem and Microbiological Outcome among Urologic Patients with Documented Gram-Negative Infections
por: Berrino, Pasquale Maria, et al.
Publicado: (2023)

Meropenem therapy in extracorporeal membrane oxygenation patients: an ongoing pharmacokinetic challenge
por: Honore, Patrick M., et al.
Publicado: (2015)

Emergence of meropenem and levofloxacin resistance in Burkholderia pseudomallei in Taiwan
por: Wu, Pin-Han, et al.
Publicado: (2023)

Clinical pharmacokinetics of 3-h extended infusion of meropenem in adult patients with severe sepsis and septic shock: implications for empirical therapy against Gram-negative bacteria
por: Kothekar, Amol T., et al.
Publicado: (2020)

Meropenem and piperacillin/tazobactam prescribing in critically ill patients: does augmented renal clearance affect pharmacokinetic/pharmacodynamic target attainment when extended infusions are used?
por: Carlier, Mieke, et al.
Publicado: (2013)

Population Pharmacokinetics of Continuous-Infusion Meropenem in Febrile Neutropenic Patients with Hematologic Malignancies: Dosing Strategies for Optimizing Empirical Treatment against Enterobacterales and P. aeruginosa
por: Cojutti, Pier Giorgio, et al.
Publicado: (2020)

Continuous infusion of meropenem–vaborbactam for a KPC-3-producing Klebsiella pneumoniae bloodstream infection in a critically ill patient with augmented renal clearance
por: Larcher, Romaric, et al.
Publicado: (2023)

Comment on “Continuous clonidine infusion: an alternative for children on mechanical ventilation”
por: Zhao, Yanxue, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_t25v4n1otjg9pb1og9n0uuk8b8